Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results From Phase 2 Radiant Study Of Remlifanserin For The Treatment Of Alzheimer’S Disease Psychosis

By Reuters News

Sept 24 (Reuters) - Acadia Pharmaceuticals Inc. ACAD.O:

  • ACADIA PHARMACEUTICALS ANNOUNCES PHASE 3 ENABLING TOPLINE RESULTS FROM PHASE 2 RADIANT STUDY OF REMLIFANSERIN FOR THE TREATMENT OF ALZHEIMER’S DISEASE PSYCHOSIS (ADP)

  • ACADIA PHARMACEUTICALS - REMLIFANSERIN DEMONSTRATED FAVORABLE SAFETY PROFILE WITH ADVERSE EVENT RATES SIMILAR TO PLACEBO

  • ACADIA: NARROWLY MISSED PRIMARY ENDPOINT OF SAPS H+D (P=0.0603) WITH SIGNIFICANCE (NOMINAL) ON KEY SECONDARY ENDPOINT OF CGI-S-ADP (P=0.0077)

  • ACADIA PHARMACEUTICALS: TO CONTINUE ENROLLING 2 ONGOING PHASE 3 STUDIES EVALUATING REMLIFANSERIN IN ADP, TO IMPLEMENT AMENDMENTS TO PHASE 3 PROGRAM

  • ACADIA: DATASET SUGGESTS NO NEGATIVE IMPACT ON MOTOR SYMPTOMS OR COGNITION; NO DEATHS IN REMLIFANSERIN TREATMENT ARMS

Further company coverage: ACAD.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.